Boehringer Ingelheim's new generation thrombolytic drug Meltingin has been approved in China for the treatment of acute ischemic stroke.

Boehringer Ingelheim announced that the China National Medical Products Administration has officially approved Meetingl for the treatment of acute ischemic stroke within 4.5 hours of onset.